Advisory Research Inc. maintained its stake in shares of NxStage Medical, Inc. (NASDAQ:NXTM) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 190,406 shares of the medical device company’s stock at the end of the second quarter. Advisory Research Inc. owned about 0.29% of NxStage Medical worth $5,109,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. CWM LLC acquired a new position in NxStage Medical in the 2nd quarter valued at $2,684,000. Birchview Capital LP raised its holdings in NxStage Medical by 21.3% in the 2nd quarter. Birchview Capital LP now owns 34,200 shares of the medical device company’s stock valued at $857,000 after acquiring an additional 6,000 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in NxStage Medical by 0.5% in the 1st quarter. Bank of New York Mellon Corp now owns 639,866 shares of the medical device company’s stock valued at $17,168,000 after acquiring an additional 2,914 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in NxStage Medical by 67.9% in the 1st quarter. Russell Investments Group Ltd. now owns 28,847 shares of the medical device company’s stock valued at $773,000 after acquiring an additional 11,668 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its holdings in NxStage Medical by 7.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 277,899 shares of the medical device company’s stock valued at $7,457,000 after acquiring an additional 18,189 shares in the last quarter. 92.66% of the stock is owned by hedge funds and other institutional investors.

Shares of NxStage Medical, Inc. (NASDAQ:NXTM) traded up 0.22% during trading on Tuesday, hitting $27.43. The stock had a trading volume of 75,416 shares. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80. The company’s market cap is $1.81 billion. The firm’s 50 day moving average is $27.81 and its 200 day moving average is $25.84.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.03). NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The firm had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. During the same period last year, the firm earned ($0.03) earnings per share. The company’s revenue for the quarter was up .0% compared to the same quarter last year. Equities research analysts anticipate that NxStage Medical, Inc. will post ($0.05) EPS for the current fiscal year.

Several equities analysts have weighed in on the company. Zacks Investment Research cut NxStage Medical from a “hold” rating to a “sell” rating in a report on Tuesday. Leerink Swann cut NxStage Medical from an “outperform” rating to a “market perform” rating and lifted their price objective for the company from $28.00 to $30.00 in a report on Tuesday, August 22nd. BTIG Research cut NxStage Medical from a “buy” rating to a “neutral” rating in a report on Friday, August 11th. Stephens cut NxStage Medical from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $33.00 to $30.00 in a report on Wednesday, August 9th. Finally, Jefferies Group LLC cut NxStage Medical from a “buy” rating to a “hold” rating and dropped their price objective for the company from $33.00 to $30.00 in a report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating and eight have issued a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $30.25.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/10/10/advisory-research-inc-has-5109000-holdings-in-nxstage-medical-inc-nxtm.html.

In other news, SVP Winifred L. Swan sold 3,500 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $29.21, for a total transaction of $102,235.00. Following the transaction, the senior vice president now directly owns 16,270 shares of the company’s stock, valued at $475,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Joseph E. Turk, Jr. sold 7,000 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $22.98, for a total value of $160,860.00. Following the transaction, the president now directly owns 82,903 shares in the company, valued at $1,905,110.94. The disclosure for this sale can be found here. Insiders have sold 50,400 shares of company stock worth $1,406,020 over the last ninety days. Insiders own 4.70% of the company’s stock.

NxStage Medical Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.